Galmed Pharmaceuticals
GLMD
20 hedge funds and large institutions have $878K invested in Galmed Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 6 closing their positions.
0.01% less ownership
Funds ownership: 0.05% → 0.05% (-0.01%)
9% less funds holding
Funds holding: 22 → 20 (-2)
28% less capital invested
Capital invested by funds: $1.21M → $878K (-$336K)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$24.4K |
| 2 |
VF
Virtu Financial
New York
|
+$18.9K |
| 3 |
Morgan Stanley
New York
|
+$14.1K |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$7.84K |
| 5 |
AF
Allworth Financial
Folsom,
California
|
+$107 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$234K |
| 2 |
Millennium Management
New York
|
-$10.5K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$10.2K |
| 4 |
Jane Street
New York
|
-$8.37K |
| 5 |
SG
StoneX Group
New York
|
-$5.28K |
GLMD Hedge Fund Activity: Q1 2023 in Review
20 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q1 2023, worth a combined $878K — down 28% from $1.21M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of GLMD and 4 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 2 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $24.4K. The largest seller was BVF Inc, cutting an estimated $234K.
- 20 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q1 2023, down from 22 in Q4 2022.
- Funds reported $878K of Galmed Pharmaceuticals stock for Q1 2023, down 28% quarter-over-quarter.
- 4 funds opened new Galmed Pharmaceuticals positions in Q1 2023 and 6 closed out, a net change of -2 holders.
- The largest Galmed Pharmaceuticals buyer in Q1 2023 was Citadel Advisors, an estimated $24.4K added.
- The largest Galmed Pharmaceuticals seller in Q1 2023 was BVF Inc, an estimated $234K sold.
Based on aggregated 13F filings for Q1 2023.